Karyopharm Therapeutics is a biopharmaceutical company pioneering nuclear export inhibition to develop differentiated therapies for cancer patients. They are building on an established commercial foundation in multiple myeloma while fostering a collaborative, fast-moving environment where individual contributions are visible and valued.